v3.26.1
Share-Based Compensation
3 Months Ended
Mar. 31, 2026
Share-Based Payment Arrangement [Abstract]  
Share-Based Compensation

Note 6: Share-Based Compensation

 

Description of Equity Plans

 

The 2021 Equity Incentive Award Plan (the “2021 Plan”) was adopted by the Company’s Board of Directors on April 9, 2021 and approved by the Company’s Annual Meeting of Shareholders (the “Annual Meeting”) on June 11, 2021. The 2021 Plan serves as a successor to the Company’s 2011 Equity Incentive Plan (the “2011 Plan”). Since the adoption of the 2021 Plan, all equity awards were made from the 2021 Plan, and no additional awards will be granted under the 2011 Plan. The 2021 Plan provides for the issuance of a variety of share-based compensation awards, including stock options, restricted stock awards, restricted stock unit awards, performance awards, dividend equivalents awards, deferred stock awards, stock payment awards and stock appreciation rights. As of the effective date of the 2021 Plan, the number of shares authorized for issuance under the 2021 Plan was increased by 3,000,000 shares, in addition to any shares remaining available for grant under the 2011 Plan.

 

As of March 31, 2026, the Company had 5,635,415 stock options outstanding and 189,682 unvested restricted stock units in addition to 1,536,508 shares of common stock available for grant under the 2021 Plan. As of December 31, 2025, the Company had 5,362,722 stock options outstanding and 64,656 unvested restricted stock units, in addition to 2,208,257 shares of common stock available for grant under the 2021 Plan.

 

Stock Options

 

Options are granted to purchase common stock at prices that are equal to the fair value of the common stock on the date the option is granted. Vesting is determined by the Board of Directors at the time of grant. The term of any stock option awards under the Company’s 2011 Plan and 2021 Plan is ten years, except for certain options granted to the contractors, which are two to five years.

 

The grant-date fair value of each option grant is estimated using the Black-Scholes option pricing model and amortized on a straight-line basis over the requisite service period, which is generally the vesting period, for each separately vesting portion of the award as if the award was, in substance, multiple awards. Use of a valuation model requires management to make certain assumptions with respect to selected model inputs, including the following.

 

 

Risk-free interest rate. The risk-free interest rate is based on U.S. Treasury rates with securities approximating the expected lives of options at the date of grant.

 

Expected dividend yield. The expected dividend yield is zero, as the Company has never paid dividends to common shareholders and does not currently anticipate paying any in the foreseeable future.

 

Expected stock price volatility. The expected stock price volatility was calculated based on the Company’s own volatility. The Company reviews its volatility assumption on an annual basis.

 

Expected life of option. The expected life of option was based on the contractual term of the option and expected employee exercise and post-vesting employment termination behavior. The Company uses the weighted average vesting period and contractual term of the option as the best estimate of the expected life of a new option.

 

The assumptions used in the Black-Scholes option pricing model for stock options granted for the three months ended March 31, 2026, are as follows:

 

Risk-free interest rate   3.8% - 3.9%
Expected dividend yield    %
Expected stock price volatility   72.2-76.5%
Expected life of options (in years)   5.5-6.3 

 

The following table summarizes the stock option activities for the three months ended March 31, 2026:

 

           Weighted-Average     
       Weighted-Average   Remaining Contractual   Aggregate Intrinsic 
   Shares   Exercise Price   Term (Years)   Value 
Outstanding at December 31, 2025   5,362,722   $2.83    4.73   $ 
Granted (1)   516,250    0.94           
Exercised                  
Expired (2)   (243,557)   1.62           
Cancelled                  
Outstanding at March 31, 2026   5,635,415   $2.71    5.17   $ 
                     
Exercisable at March 31, 2026   4,557,278   $3.05    4.29   $ 

 

Notes:

 

(1) Options granted:

 

  Annual share-based compensation awards on January 2, 2026, with an exercise price of $0.94, including: (a) 287,750 stock options granted to executives and key personnel, vesting upon one year anniversary, or annually in equal installments over four years, (b) 185,000 stock options granted to members of the Board of Directors, vesting upon one year anniversary, (c) 23,500 stock options granted to employees, vesting annually in equal installments over four years, and (d) 20,000 stock options granted to a consultant, vesting upon one year anniversary.

 

(2) Options expired:

 

  (a) 50,000 stock options with an exercise price of $1.82 per share granted to members of the Board of Directors, (b) 191,057 stock options with an exercise price of $1.57 per share granted to a key personnel, (c) 2,500 stock options with an exercise price of $1.66 per share granted to a former employee.

 

 

Restricted Stock Units

 

Restricted stock units (the “RSUs”) are granted subject to certain restrictions. Vesting conditions are determined at the discretion of the Board of Directors. The fair market value of RSUs is generally determined based on the closing market price of the stock on the grant date.

 

The following table summarizes the restricted stock award activity for the three months ended March 31, 2026:

 

       Weighted-Average 
       Grant Date 
   Shares   Fair Value 
Outstanding at December 31, 2025   64,656   $1.74 
Granted (1)   375,931    0.93 
Vested (2)   (250,905)   1.15 
Unvested shares forfeited        
Outstanding at March 31, 2026   189,682   $0.91 

 

 

Notes:

 

(1) On January 2, 2026, the Company granted 119,682 restricted stock units, vesting upon one year anniversary, to the Board of Directors as a result of reduction in director cash compensation for 2026, and an aggregate of 186,249 restricted stock units, vested in full, to executives and key personnel in lieu of cash bonus earned for the year ended December 31, 2025.
   
  On March 1, 2026, the Company granted two consultants a total of 70,000 restricted stock units, vesting upon the satisfaction of the applicable time and performance criteria.
   
(2) Represents the vesting of 186,249 RSUs granted to executives and key personnel, and 64,656 RSUs granted to the Board of Directors.

 

Compensation Expenses

 

We recognize all share-based payments to employees and our Board of Directors, as non-cash compensation expense, in research and development expenses or general and administrative expenses in the consolidated statement of operations, and these charges had no impact on the Company’s reported cash flows. Stock-based compensation expense is calculated on the grant date fair values of such awards, and recognized each period based on the value of the portion of share-based payment awards that is ultimately expected to vest during the period. Forfeitures are recorded as they occur. For the three months ended March 31, 2026, no forfeitures were recorded.

 

For performance-based awards, the Company recognizes related stock-based compensation expenses based upon its determination of the potential likelihood of achievement of the specified performance conditions at each reporting date.

 

Total non-cash share-based compensation expense was allocated among the following expense categories:

 

   2026   2025 
   Three Months Ended March 31, 
   2026   2025 
General and administrative  $129,033   $207,996 
Research and development   10,266    17,034 
Total  $139,299   $225,030 

 

The following table summarizes the Company’s non-cash share-based compensation expense allocation between options and restricted stock units:

 

   2026   2025 
   Three Months Ended March 31, 
   2026   2025 
Share based compensation expense - stock option  $107,741   $177,294 
Share based compensation expense - restricted stock units   31,558    47,736 
Total  $139,299   $225,030 

 

Warrants

 

On August 1, 2025, in connection with the services the Underwriter provided to the Company in the Offering, the Company issued to the Underwriter warrants to purchase up to 302,600 shares of common stock (the “Underwriter Warrants”), representing 5.0% of the total shares sold in the Offering. The Underwriter Warrants are exercisable at a price of $1.0925 per share, at any time and from time to time, in whole or in part, from January 28, 2026 until August 1, 2030. As of March 31, 2026, there were 302,600 outstanding warrants to purchase common stock. See Note 7 Shareholder’s Equity.

 

The warrants were accounted for as equity-classified instruments under ASC 718. The fair value of the warrants, determined using the Black-Scholes option pricing model, was estimated to be $0.58 at the issuance date and was recorded as a component of additional paid-in capital, with a corresponding reduction to offering proceeds as an offering cost. The assumptions used in the Black-Scholes model included:

 

Risk-free interest rate:   3.67%
Expected dividend yield:   0%
Expected stock price volatility:   64.97%
Expected life of warrants (in years)     5.0